Aclaris Therapeutics: Biosion reports 4.7% stake
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Aclaris Therapeutics, Inc. (ACRS) is the issuer whose common stock Biosion, Inc. and its wholly owned subsidiary Bonita Biotech (HK) Limited each reported beneficially owning in the same 7,521,300-share position, representing 4.7% of the class. Bonita holds the shares of record, and both reporting persons reported sole voting and dispositive power over them.
Key Figures
Key Terms
Beneficially Owned technical
Sole Voting Power technical
Sole Dispositive Power technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How was the reported 4.7% ACRS ownership calculated?
AI-generated analysis. How Rhea-AI works. Not financial advice.